06.30.23 -- Advancing mRNA Therapeutic Manufacturing

Speed-to-market is critical, but the path to developing a commercial mRNA-lipid nanoparticle (LNP) drug product is complex, with challenges at every stage. Learn why single-use technology is gaining attention for its ability to facilitate a reliable and robust manufacturing process for biopharma manufacturers looking to scale up mRNA therapeutics.

Each regulatory phase of mRNA-based therapeutic development consists of specific goals, steps, and end points. There are also some unique challenges and risks. Understand the fundamentals of manufacturing mRNA-LNP vaccines and therapeutics from discovery through to commercialization.

Process development is a challenge for any drug developer, and evaluation of both upstream and downstream steps is needed to gain end-to-end process insight across the entire manufacturing workflow. Discover how a robust manufacturing process ensures the safety and efficacy of mRNA-LNPs.

mRNA technology is not yet mature and with no standardized manufacturing protocols for producing mRNA drug products, scaling up the formulation remains one of the biggest challenges. Learn about the importance of evading impurities in lipids, the significance of the biological readout, and the future of genomic medicines.

Advances in genome sequencing and bioinformatics have led to a wealth of information to treat disease and make disease targets druggable. Gain insight into technologies and solutions for the delivery and economic challenges of developing genomic medicines and realizing their full potential.